Table 1 Patient baseline characteristics.

Male sex, n (%)

37 (59.7)

40 (64.5)

0.579

Patients with isolated systolic hypertension, n (%)

17 (27.4)

14 (22.5)

0.534

Age, years

71.7 ± 4.3

71.2 ± 4.0

0.560

BMI, kg/m²

25.8 ± 2.3

25.5 ± 2.3

0.565

eGFR, mL/min/1.73 m²

81.5 ± 8.6

83.0 ± 7.0

0.285

HbA1c, %

7.7 ± 1.1

7.7 ± 0.5

0.887

FPG, mmol/L

8.6 ± 1.0

8.4 ± 0.8

0.252

Years since diagnosis of type 2 diabetes, n (%)

≤ 1

7 (11.3)

8 (12.9)

0.064

> 1 to 5

19 (30.6)

11 (17.7)

> 5 to 10

22 (35.5)

16 (25.8)

> 10

14 (22.6)

27 (43.5)

SBP (office measurement), mmHg

159.5 ± 8.0

157.1 ± 10.1

0.151

SBP (mean over 24 h), mmHg

150.8 ± 37.2

153.0 ± 36.8

0.384

DBP (office measurement), mmHg

97.7 ± 4.7

98.5 ± 2.0

0.278

DBP (mean over 24 h), mmHg

95.4 ± 22.3

96.2 ± 23.4

0.171

Pulse rate (mean 24 h), bpm

77.8 ± 5.2

77.3 ± 8.2

0.705

Serum insulin (uU/mL)

14.2 ± 2.9

14.4 ± 3.7

0.704

HOMA-IR

5.5 ± 1.4

5.4 ± 1.5

0.828

FMD (%)

7.1 ± 1.0

7.0 ± 1.0

0.289

cPWV(m/s)

6.7 ± 1.4

6.4 ± 0.8

0.085

Antihypertensive drugs

Diuretic drugs

10 (16.1)

12 (19.4)

0.638

Calcium channel blockers

25 (40.3)

29 (46.8)

0.469

ACEI/ARB

43 (69.4)

45 (72.6)

0.692

β-blockers

27 (43.5)

32 (51.6)

0.369

Anti-diabetic drugs

Insulin

7 (11.3)

11 (17.7)

0.308

Sulfonylurea

14 (22.6)

19 (30.6)

0.310

DPP4 inhibitor

27 (43.5)

31 (50.0)

0.472

Metformin

47 (75.8)

43 (69.4)

0.421

Lipid-lowering agents

Statins

45 (72.6)

50 (80.6)

0.289

Fibrates

13 (21.0)

19 (30.6)

0.218

Patients with BP ≥ 130/80 mmHg (ABPM) at baseline, Mean 24-h SBP

186.1 ± 21.4

189.5 ± 21.6

0.895

Patients with BP ≥ 130/80 mmHg (ABPM) at baseline, mean 24-h DBP

114.7 ± 23.9

116.1 ± 24.1

0.571

Patients with BP < 130/80 mmHg (ABPM) at baseline, mean 24-h SBP

123.5 ± 5.7

121.0 ± 8.1

0.366

Patients with BP < 130/80 mmHg (ABPM) at baseline, mean 24-h DBP

71.7 ± 6.9

72.5 ± 5.2

0.277